Abstract and Introduction
The Food and Drug Administration (FDA) approved 48 novel drugs and biologics in 2017. Several of these drug and drug product approvals are of benefit to the pediatric patient population. This issue of the newsletter will review these new treatment options, as well as previously approved medications given new pediatric indications and new drugs currently under FDA review.
Pediatr Pharm. 2018;24(4) © 2018 University of Virginia